2025 ONCOLOGY HIGHLIGHTS
Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Is it time to shift supportive care toward digital-assisted approaches?
Recent findings show digital tools have the potential to improve the monitoring of symptoms and psychological aspects, but they should be integrated within routine clinical practice
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Rethinking the limits of tissue-agnostic cancer therapy
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
AI & DIGITAL ONCOLOGY
AI is impacting cancer care, but also the environment
Research shows that widespread use of artificial intelligence tools is associated with high demand for energy, water and minerals
AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Will AI reduce or increase inequities in cancer care?
While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
OPINIONS
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon
OPINIONS
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon